摘要
目的：观察腹型肥胖的2型糖尿病患者应用利拉鲁肽治疗的疗效及其安全性。方法筛选20例符合入选标准的腹型肥胖2型糖尿病患者,在原有降糖药物基础上,加用利拉鲁肽0.6~1.8 mg皮下注射,1次/d。治疗随访观察12周,比较治疗前后空腹血糖（FPG）、餐后2 h血糖（2 hPG）、空腹及餐后2 h胰岛素及C肽、糖化血红蛋白（HbA1c）、体重指数（BMI）、腰围、血压、血脂的变化情况。观察并记录其不良反应。结果对采用利拉鲁肽治疗患者前后的空腹血糖、餐后2h血糖、糖化血红蛋白、体重、BMI、腰围、HOMA-β及HOMA-IR指数相互比较,其差异有统计学意义（ P〈0.05）。观察到有少数患者出现不良反应,但均能耐受治疗。结论在原有口服降糖药物基础上加用利拉鲁肽能有效降低血糖,显著降低患者体重,并能改善胰岛β细胞功能,降低血脂、血压,且发生低血糖的风险低,是2型糖尿病患者治疗的新选择。
Objective To observe the efficacy and safety of liraglutide in the treatment of abdominal obesity patient with type 2 diabetics. Methods 20 cases of abdominal obesity patients with type 2 diabetics, based on the original antidiabetic drugs, the addition of lirarupeptide 0.6~1.8 mg subcutaneous injection, 1 time/d. Treatment were followed up for 12 weeks,compared the fasting blood glucose（FPG）,2 h postprandial blood glucose（2 HPG）, fasting and 2 h postprandial insulin and C peptide,glycosylated hemoglobin（HbA1c）, body mass index（BMI）, waist circumference, blood pressure,blood lipid changes. Observe and record the adverse reactions. Results Patients with liraglutide treatment before and after the fasting blood glucose, postprandial 2 hours blood glucose, glycosylated hemoglobin, weight, BMI, waist circumference, HOMA-βand HOMA-IR index were compared, and the differences were statistically significant（P〈0.05）. Observed a few adverse reactions in patients with, but tolerated treatment. Conclusion Oral hypoglycemic drugs plus the liraglutide can effectively reduce the blood sugar, significantly reduced in patients with body weight, and can improve the function of islet beta cells, reduce blood fat, blood pressure, and low risk of hypoglycemia, is a new treatment option for patients with type 2 diabetes.
出处
《中国实用医药》
2014年第9期9-11,共3页
China Practical Medicine
关键词
利拉鲁肽
腹型肥胖
2型糖尿病
疗效
Liraglutide
Abdominal obesity
Type 2 diabetes
Efficacy
